Advances in bioartificial liver devices

Allen, Julie K.

doi:10.1053/jhep.2001.26753

Cited by 311 publications

(198 citation statements)

References 127 publications

Supporting

Mentioning

190

Contrasting

Unclassified

Order By: Relevance

“…Bioartificial liver (BAL) devices have gone through many iterations whilst being developed as an extracorporeal device for the treatment of liver failure [24]. Early flat plate and monolayer bioreactors exhibited uniform cell distributions and microenvironments, but presented complex scale up issues and a low surface area to volume ratio [25] [26].…”

Section: Perspectives From Established Systems Used Within Pharmaceutmentioning

confidence: 99%

The use of bioreactors as in vitro models in pharmaceutical research

Ginai

Elsby

Hewitt

et al. 2013

Drug Discovery Today

View full text Add to dashboard Cite

Word TeaserThe development of dynamic 3D bioreactor based systems as in vitro models for use in DMPK studies. Author BiographiesMaaria Ginai graduated with a first Class Bachelors degree with honours in Biomedical Science from the University of Kent (UK) in 2010. She is currently studying a BBSRC CASEfunded PhD at the Centre for Biological Engineering at Loughborough University in the area of bioartificial device progression to in vitro models for use in the pharmaceutical industry. This project is supported by AstraZeneca.Christopher J. Hewitt has a first Class Bachelors degree in Biology from Royal Holloway College, University of London (UK) and a PhD in Chemical Engineering from the University of Birmingham (UK). He is Director of the £7.3M EPSRC Doctoral Training Centre in Regenerative Medicine and co-founder of the £2M Centre for Biological Engineering at Loughborough University (UK). He also leads the Cell Technologies research group whose work spans the Engineering/Life science interface seeking to understand the interaction of the organism with the engineering environment within such diverse areas as microbial fermentation, bio-transformation, cell culture and mostly recently regenerative medicine bioprocessing.Karen Coopman has a first Class Bachelors degree in Pharmacology from the University of Bristol (UK) and a PhD from the Department of Pharmacy and Pharmacology at the University of Bath (UK). She was appointed to a lectureship at Loughborough University, where she is the Operations Manager of the EPSRC-funded Doctoral Training Centre in Regenerative Medicine. She co-leads the Cell Technologies research group within University's Centre for Biological Engineering and is currently a member of the EPSRC's Early Career Forum in Manufacturing Research. The overarching themes of Karen's research are the manufacture of cellular therapies and the use of cells in the drug discovery process. AbstractBringing a new drug to market is costly in terms of capital and time investments, and any development issues encountered in late stage clinical trials may often be due to in vitro -in vivo extrapolations (IVIVE) not accurately reflecting clinical outcome. In the discipline of drug metabolism and pharmacokinetics (DMPK), current in vitro cellular methods do not provide the 3D structure and function of organs found in vivo, so new dynamic methods need to be established to aid improvement of IVIVE. This review will highlight the importance of model progression into dynamic systems for use within drug development, focussing on devices developed currently in the areas of the liver and blood-brain barrier, and the potential to develop models for other organ systems such as the kidney.

show abstract

Section: Perspectives From Established Systems Used Within Pharmaceutmentioning

confidence: 99%

The use of bioreactors as in vitro models in pharmaceutical research

Ginai

Elsby

Hewitt

et al. 2013

Drug Discovery Today

View full text Add to dashboard Cite

show abstract

“…Bioartificial or hybrid devices combine the best of both biological and non-biological techniques. [17][18][19][20] Because most of the data with regard to extracorporeal liver support are available for non-biological support systems, we will further focus on these techniques.…”

Section: Which Types Of Liver Support Are Available?mentioning

confidence: 99%

Review article: non‐biological liver support in liver failure

Laleman¹,

Wilmer²,

Evenepoel³

et al. 2006

Aliment Pharmacol Ther

View full text Add to dashboard Cite

SUMMARYLiver failure, whether acute or acute-on-chronic, remains an important cause of morbidity and mortality. The lack of liver detoxification, metabolic and regulatory functions of the liver leads to life-threatening complications, such as renal failure, altered immune response, hepatic coma and systemic haemodynamic dysfunction, eventually culminating in multiorgan failure.Current medical therapy involves the management of the precipitating event and treatment of complications until the liver eventually recovers, leaving us with no other treatment options than transplantation if these attempts fail. However, the shortage in cadaveric organs and other transplant-related problems, have prompted the need for alternative methods to provide liver support.As liver failure is often potentially reversible, considerable effort has been invested in the development of liver support systems. Currently, most of the experience is available for non-biological support systems. They represent the focus of this review, which aims to define the goals of liver support, to describe the design of the different existing devices and to analyse the available data to determine their current status in the management of patients with liver failure.

show abstract

“…BMSCs may be an attractive source of hepatocytes for use in a bio-artificial liver machine. 31 They would be free of the theoretical risks of transmitting unknown infective agents from porcine hepatocytes and are not derived from potentially tumorgenic immortalised cell lines. Clearly if one could identify the factors that control HSC differentiation into hepatocytes perhaps this would enable one to harvest stem cells either from peripheral or cord blood, expand this population in vitro and differentiate these cells into functioning hepatocytes.…”

Section: Gene Therapymentioning

confidence: 99%